跳至主要内容
临床试验/NCT00680550
NCT00680550已完成不适用

Indications for Diagnosis, Arrhythmia and Monitoring of Reveal XT.

Medtronic BRC55 个研究点 分布在 14 个国家目标入组 1,003 人开始时间: 2008年4月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
1,003
试验地点
55
主要终点
descriptive: clinical indications for Reveal XT

研究概览

简要总结

To describe the clinical indications for Reveal XT in diagnosis and continuous monitoring of arrhythmia and to explore the clinical applications and outcome of arrhythmia monitoring on patient care.

详细描述

Improving the diagnosis and management of cardiac rhythm disturbances remains a major challenge for physicians. Limitations of current cardiac arrhythmia monitoring using ECG, holters or event recorders are that these methods are non-continuous and/or automatic arrhythmia detection is often impossible. The Medtronic Reveal XT Insertable Cardiac Monitor is a programmable device which continuously monitors the patient's subcutaneous ECG and provides information regarding arrhythmia episodes, long term trending of AF burden, patient's activity and heart rate variability. The Reveal XT records cardiac information in response to patient activation and automatically detected arrhythmias thereby offering advantages over conventional tools for long-term arrhythmia monitoring with regard to compliance and recording time.

The clinical applications for Reveal XT are varied. Diagnostic, arrhythmia monitoring and arrhythmia management functions can be discriminated.

This study is a prospective, observational, multicenter international post-market study. The results of this study will describe the different patient groups for which the Reveal XT is being used for the diagnosis and monitoring of various cardiac arrhythmias. This study will also collect data regarding the clinical consequences of using the Reveal XT and the influence of Reveal XT data on clinical care pathways. The physician as well as the patient's satisfaction with the device will be evaluated. The study will be conducted in 60-100 centers primarily in Europe. It is expected that 800-1000 patients will be enrolled.

研究设计

研究类型
Observational
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient implanted or scheduled for an implant with a Reveal XT Insertable Cardiac Monitor System for arrhythmia diagnosis or monitoring
  • Patient must be willing to sign a Patient Data Release Form (or Informed Consent where applicable)

排除标准

  • Enrollment outside a 30-day window from the planned/performed Reveal XT implant procedure (from 15 days pre-implant until 15 days post implant)
  • Patient is implanted with a pacemaker, ICD, CRT-device or an implantable hemodynamic monitoring system
  • Unwillingness or inability to cooperate or give written informed consent or, if the patient is a minor and the legal guardian refuses to give consent

结局指标

主要结局

descriptive: clinical indications for Reveal XT

时间窗: 2008-2012

To describe the patient population implanted with a Reveal XT for arrhythmia diagnosis and monitoring

次要结局

未报告次要终点

研究者

发起方
Medtronic BRC
申办方类型
Industry
责任方
Sponsor

研究点 (55)

Loading locations...

相似试验